Manager of Preclinical Studies

DAVRON CV: Candidate 1910856

TRANSLATIONAL SCIENTIST | ONCOLOGY DISCOVERY | IN VITRO & IN VIVO MODELS

Core Expertise

• Directed end-to-end in vitro and in vivo oncology studies with strict protocol and quality compliance.
• Designed and validated robust cell-based, biochemical, and molecular assays for drug discovery.
• Engineered disease-relevant cell models using CRISPR-Cas9 to enable target validation studies.
• Operated orthotopic and tumor model studies, including animal injections and preclinical efficacy testing.
• Communicated scientific strategy to sponsors and cross-functional teams, delivering projects on time and budget.

Project Background

• Advanced early-stage oncology programs through target validation, high-throughput screening, and mechanistic follow-up.
• Executed pharmacodynamics and pharmacokinetics-linked efficacy studies to inform candidate progression decisions.
• Developed and optimized assays including ELISA, western blot, Luminex, and cell viability screens.
• Coordinated multi-site CRO partnerships to meet timelines and maintain data quality across studies.
• Contributed to peer-reviewed publications on leukemia biology and epigenetic regulators in hematopoiesis.

Key Skills

• Pharmacodynamics (PD) | Pharmacokinetics (PK) | Efficacy study design
• CRISPR-Cas9 genome editing | Cell line engineering | Model development
• In vivo tumor models | Orthotopic injections | IACUC and AAALAC familiarity
• Assay development: ELISA, western blot, Luminex, viability assays, HTS
• Data analysis and scientific reporting | Experimental design and troubleshooting
• Project leadership | Client liaison | Scheduling and budget oversight
• R | Statistical foundations for experimental analysis

Education

• Ph.D., Cell Biology — Medical College of Wisconsin
• B.S., Biology — University of Wisconsin–Parkside

Awards & Recognition

• Statistics Foundations 1: The Basics (certificate)
• Learning R (certificate)

Why Interview this Candidate?

A PhD-trained translational scientist who has led both in vitro and in vivo oncology studies and published on leukemia biology. They combine assay development, CRISPR-engineered models, and PD/PK expertise to accelerate preclinical decisions. Their sponsor-facing experience and personal commitment to advancing cancer therapies enable immediate contributions to preclinical teams.